|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 23576 |
FusionGeneSummary for NCEH1_BCL2L1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: NCEH1_BCL2L1 | Fusion gene ID: 23576 | Hgene | Tgene | Gene symbol | NCEH1 | BCL2L1 | Gene ID | 57552 | 598 |
| Gene name | neutral cholesterol ester hydrolase 1 | BCL2 like 1 | |
| Synonyms | AADACL1|NCEH | BCL-XL/S|BCL2L|BCLX|Bcl-X|PPP1R52 | |
| Cytomap | 3q26.31 | 20q11.21 | |
| Type of gene | protein-coding | protein-coding | |
| Description | neutral cholesterol ester hydrolase 1arylacetamide deacetylase-like 1 | bcl-2-like protein 1apoptosis regulator Bcl-Xprotein phosphatase 1, regulatory subunit 52 | |
| Modification date | 20180523 | 20180527 | |
| UniProtAcc | Q6PIU2 | Q07817 | |
| Ensembl transtripts involved in fusion gene | ENST00000475381, ENST00000273512, ENST00000538775, ENST00000543711, | ENST00000376062, ENST00000376055, ENST00000307677, ENST00000420653, | |
| Fusion gene scores | * DoF score | 6 X 3 X 6=108 | 5 X 3 X 5=75 |
| # samples | 6 | 5 | |
| ** MAII score | log2(6/108*10)=-0.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: NCEH1 [Title/Abstract] AND BCL2L1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | BCL2L1 | GO:0001836 | release of cytochrome c from mitochondria | 9843949 |
| Tgene | BCL2L1 | GO:0019050 | suppression by virus of host apoptotic process | 15231831 |
| Tgene | BCL2L1 | GO:0034097 | response to cytokine | 9184696 |
| Tgene | BCL2L1 | GO:0043066 | negative regulation of apoptotic process | 7650367|9388232 |
| Tgene | BCL2L1 | GO:0046902 | regulation of mitochondrial membrane permeability | 9843949 |
| Tgene | BCL2L1 | GO:0051881 | regulation of mitochondrial membrane potential | 9843949 |
| Tgene | BCL2L1 | GO:1900118 | negative regulation of execution phase of apoptosis | 20673843 |
| Tgene | BCL2L1 | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 26582200 |
| Tgene | BCL2L1 | GO:1902230 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 16608847 |
| Tgene | BCL2L1 | GO:1903077 | negative regulation of protein localization to plasma membrane | 21041309 |
| Tgene | BCL2L1 | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 12011449 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | CESC | TCGA-LP-A7HU-01A | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000475381 | ENST00000376062 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000475381 | ENST00000376055 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000475381 | ENST00000307677 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000475381 | ENST00000420653 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| In-frame | ENST00000273512 | ENST00000376062 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000273512 | ENST00000376055 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000273512 | ENST00000307677 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000273512 | ENST00000420653 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| In-frame | ENST00000538775 | ENST00000376062 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000538775 | ENST00000376055 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000538775 | ENST00000307677 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| Frame-shift | ENST00000538775 | ENST00000420653 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| 5UTR-3CDS | ENST00000543711 | ENST00000376062 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| 5UTR-3CDS | ENST00000543711 | ENST00000376055 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| 5UTR-3CDS | ENST00000543711 | ENST00000307677 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
| 5UTR-3CDS | ENST00000543711 | ENST00000420653 | NCEH1 | chr3 | 172428637 | - | BCL2L1 | chr20 | 30253889 | - |
Top |
FusionProtFeatures for NCEH1_BCL2L1 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| NCEH1 | BCL2L1 |
| Potent inhibitor of cell death. Inhibits activation ofcaspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing therelease of the caspase activator, CYC1, from the mitochondrialmembrane. Also acts as a regulator of G2 checkpoint andprogression to cytokinesis during mitosis. Isoform Bcl-X(L) also regulates presynaptic plasticity,including neurotransmitter release and recovery, number of axonalmitochondria as well as size and number of synaptic vesicleclusters. During synaptic stimulation, increases ATP availabilityfrom mitochondria through regulation of mitochondrial membrane ATPsynthase F(1)F(0) activity and regulates endocytic vesicleretrieval in hippocampal neurons through association with DMN1Land stimulation of its GTPase activity in synaptic vesicles. Mayattenuate inflammation impairing NLRP1-inflammasome activation,hence CASP1 activation and IL1B release (PubMed:17418785).{ECO:0000269|PubMed:17418785}. Isoform Bcl-X(S) promotes apoptosis. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000475381 | - | 1 | 5 | 1_4 | 46 | 409 | Topological domain | Cytoplasmic |
| Hgene | NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000475381 | - | 1 | 5 | 5_25 | 46 | 409 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
| Tgene | >BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376055 | - | 1 | 3 | 129_148 | 125 | 171 | Motif | Note=BH1 |
| Tgene | >BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376055 | - | 1 | 3 | 180_195 | 125 | 171 | Motif | Note=BH2 |
| Tgene | >BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000307677 | - | 1 | 3 | 210_226 | 188 | 234 | Transmembrane | Helical |
| Tgene | >BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376055 | - | 1 | 3 | 210_226 | 125 | 171 | Transmembrane | Helical |
| Tgene | >BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376062 | - | 0 | 2 | 210_226 | 188 | 234 | Transmembrane | Helical |
| Tgene | >BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000420653 | - | 1 | 3 | 210_226 | 188 | 234 | Transmembrane | Helical |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | >NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000475381 | - | 1 | 5 | 113_115 | 46 | 409 | Motif | Involved in the stabilization of the negatively charged intermediate by the formation of the oxyanion hole |
| Hgene | >NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000543711 | - | 1 | 4 | 113_115 | -11 | 276 | Motif | Involved in the stabilization of the negatively charged intermediate by the formation of the oxyanion hole |
| Hgene | >NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000475381 | - | 1 | 5 | 26_408 | 46 | 409 | Topological domain | Lumenal |
| Hgene | >NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000543711 | - | 1 | 4 | 1_4 | -11 | 276 | Topological domain | Cytoplasmic |
| Hgene | >NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000543711 | - | 1 | 4 | 26_408 | -11 | 276 | Topological domain | Lumenal |
| Hgene | >NCEH1 | chr3:172428637 | chr20:30253889 | ENST00000543711 | - | 1 | 4 | 5_25 | -11 | 276 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000307677 | - | 1 | 3 | 129_148 | 188 | 234 | Motif | Note=BH1 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000307677 | - | 1 | 3 | 180_195 | 188 | 234 | Motif | Note=BH2 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000307677 | - | 1 | 3 | 4_24 | 188 | 234 | Motif | Note=BH4 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000307677 | - | 1 | 3 | 86_100 | 188 | 234 | Motif | Note=BH3 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376055 | - | 1 | 3 | 4_24 | 125 | 171 | Motif | Note=BH4 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376055 | - | 1 | 3 | 86_100 | 125 | 171 | Motif | Note=BH3 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376062 | - | 0 | 2 | 129_148 | 188 | 234 | Motif | Note=BH1 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376062 | - | 0 | 2 | 180_195 | 188 | 234 | Motif | Note=BH2 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376062 | - | 0 | 2 | 4_24 | 188 | 234 | Motif | Note=BH4 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000376062 | - | 0 | 2 | 86_100 | 188 | 234 | Motif | Note=BH3 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000420653 | - | 1 | 3 | 129_148 | 188 | 234 | Motif | Note=BH1 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000420653 | - | 1 | 3 | 180_195 | 188 | 234 | Motif | Note=BH2 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000420653 | - | 1 | 3 | 4_24 | 188 | 234 | Motif | Note=BH4 |
| Tgene | BCL2L1 | chr3:172428637 | chr20:30253889 | ENST00000420653 | - | 1 | 3 | 86_100 | 188 | 234 | Motif | Note=BH3 |
Top |
FusionGeneSequence for NCEH1_BCL2L1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_NCEH1_ENST00000475381_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_92aa MRSSCVLLTALVALAAYYVYIPLPGSVSDPWKLMLLDATFRGAQQVDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSR >In-frame_NCEH1_ENST00000273512_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_124aa MSSCRGQKVAGGLRVVSPFPLCQPAGEPSQGKMRSSCVLLTALVALAAYYVYIPLPGSVSDPWKLMLLDATFRGAQQVDTFVELYGNNAA >In-frame_NCEH1_ENST00000538775_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_124aa MSSCRGQKVAGGLRVVSPFPLCQPAGEPSQGKMRSSCVLLTALVALAAYYVYIPLPGSVSDPWKLMLLDATFRGAQQVDTFVELYGNNAA |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_NCEH1_ENST00000475381_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_276nt ATGAGGTCGTCCTGTGTCCTGCTCACCGCCCTGGTGGCGCTGGCCGCCTATTACGTCTACATCCCGCTGCCTGGCTCCGTGTCCGACCCC TGGAAGCTGATGCTGCTGGACGCCACTTTCCGGGGTGCACAGCAAGTGGATACTTTTGTGGAACTCTATGGGAACAATGCAGCAGCCGAG AGCCGAAAGGGCCAGGAACGCTTCAACCGCTGGTTCCTGACGGGCATGACTGTGGCCGGCGTGGTTCTGCTGGGCTCACTCTTCAGTCGG >In-frame_NCEH1_ENST00000273512_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_372nt ATGAGCAGCTGCCGCGGGCAGAAAGTTGCCGGAGGTCTCCGGGTGGTATCGCCCTTTCCTCTTTGCCAGCCCGCTGGCGAGCCGAGCCAG GGCAAGATGAGGTCGTCCTGTGTCCTGCTCACCGCCCTGGTGGCGCTGGCCGCCTATTACGTCTACATCCCGCTGCCTGGCTCCGTGTCC GACCCCTGGAAGCTGATGCTGCTGGACGCCACTTTCCGGGGTGCACAGCAAGTGGATACTTTTGTGGAACTCTATGGGAACAATGCAGCA GCCGAGAGCCGAAAGGGCCAGGAACGCTTCAACCGCTGGTTCCTGACGGGCATGACTGTGGCCGGCGTGGTTCTGCTGGGCTCACTCTTC >In-frame_NCEH1_ENST00000538775_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_372nt ATGAGCAGCTGCCGCGGGCAGAAAGTTGCCGGAGGTCTCCGGGTGGTATCGCCCTTTCCTCTTTGCCAGCCCGCTGGCGAGCCGAGCCAG GGCAAGATGAGGTCGTCCTGTGTCCTGCTCACCGCCCTGGTGGCGCTGGCCGCCTATTACGTCTACATCCCGCTGCCTGGCTCCGTGTCC GACCCCTGGAAGCTGATGCTGCTGGACGCCACTTTCCGGGGTGCACAGCAAGTGGATACTTTTGTGGAACTCTATGGGAACAATGCAGCA GCCGAGAGCCGAAAGGGCCAGGAACGCTTCAACCGCTGGTTCCTGACGGGCATGACTGTGGCCGGCGTGGTTCTGCTGGGCTCACTCTTC |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_NCEH1_ENST00000475381_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_2007nt AGAGCAGCGACAGAGCCTTCCTCAAACCTGTAGTGACTGCCACACTTTGCAAGGACACCGTAGAGGGGGCATGTCCGCGCTCCAACTTCC TCCCGACGCAGCCTCTGATTGGCTCCTGGGCTTATAAGAAACGCGTGAATGAGCAGCTGCCGCGGGCAGAAAGTTGCCGGAGGTCTCCGG GTGGTATCGCCCTTTCCTCTTTGCCAGCCCGCTGGCGAGCCGAGCCAGGGCAAGATGAGGTCGTCCTGTGTCCTGCTCACCGCCCTGGTG GCGCTGGCCGCCTATTACGTCTACATCCCGCTGCCTGGCTCCGTGTCCGACCCCTGGAAGCTGATGCTGCTGGACGCCACTTTCCGGGGT GCACAGCAAGTGGATACTTTTGTGGAACTCTATGGGAACAATGCAGCAGCCGAGAGCCGAAAGGGCCAGGAACGCTTCAACCGCTGGTTC CTGACGGGCATGACTGTGGCCGGCGTGGTTCTGCTGGGCTCACTCTTCAGTCGGAAATGACCAGACACTGACCATCCACTCTACCCTCCC ACCCCCTTCTCTGCTCCACCACATCCTCCGTCCAGCCGCCATTGCCACCAGGAGAACCACTACATGCAGCCCATGCCCACCTGCCCATCA CAGGGTTGGGCCCAGATCTGGTCCCTTGCAGCTAGTTTTCTAGAATTTATCACACTTCTGTGAGACCCCCACACCTCAGTTCCCTTGGCC TCAGAATTCACAAAATTTCCACAAAATCTGTCCAAAGGAGGCTGGCAGGTATGGAAGGGTTTGTGGCTGGGGGCAGGAGGGCCCTACCTG ATTGGTGCAACCCTTACCCCTTAGCCTCCCTGAAAATGTTTTTCTGCCAGGGAGCTTGAAAGTTTTCAGAACCTCTTCCCCAGAAAGGAG ACTAGATTGCCTTTGTTTTGATGTTTGTGGCCTCAGAATTGATCATTTTCCCCCCACTCTCCCCACACTAACCTGGGTTCCCTTTCCTTC CATCCCTACCCCCTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATAAAGATGCAAGGACCAGGACTCCCTC CTCACCTCTGGACTGGCTAGAGTCCTCACTCCCAGTCCAAATGTCCTCCAGAAGCCTCTGGCTAGAGGCCAGCCCCACCCAGGAGGGAGG GGGCTATAGCTACAGGAAGCACCCCATGCCAAAGCTAGGGTGGCCCTTGCAGTTCAGCACCACCCTAGTCCCTTCCCCTCCCTGGCTCCC ATGACCATACTGAGGGACCAACTGGGCCCAAGACAGATGCCCCAGAGCTGTTTATGGCCTCAGCTGCCTCACTTCCTACAAGAGCAGCCT GTGGCATCTTTGCCTTGGGCTGCTCCTCATGGTGGGTTCAGGGGACTCAGCCCTGAGGTGAAAGGGAGCTATCAGGAACAGCTATGGGAG CCCCAGGGTCTTCCCTACCTCAGGCAGGAAGGGCAGGAAGGAGAGCCTGCTGCATGGGGTGGGGTAGGGCTGACTAGAAGGGCCAGTCCT GCCTGGCCAGGCAGATCTGTGCCCCATGCCTGTCCAGCCTGGGCAGCCAGGCTGCCAAGGCCAGAGTGGCCTGGCCAGGAGCTCTTCAGG CCTCCCTCTCTCTTCTGCTCCACCCTTGGCCTGTCTCATCCCCAGGGGTCCCAGCCACCCCGGGCTCTCTGCTGTACATATTTGAGACTA GTTTTTATTCCTTGTGAAGATGATATACTATTTTTGTTAAGCGTGTCTGTATTTATGTGTGAGGAGCTGCTGGCTTGCAGTGCGCGTGCA CGTGGAGAGCTGGTGCCCGGAGATTGGACGGCCTGATGCTCCCTCCCCTGCCCTGGTCCAGGGAAGCTGGCCGAGGGTCCTGGCTCCTGA GGGGCATCTGCCCCTCCCCCAACCCCCACCCCACACTTGTTCCAGCTCTTTGAAATAGTCTGTGTGAAGGTGAAAGTGCAGTTCAGTAAT >In-frame_NCEH1_ENST00000273512_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_2007nt AGAGCAGCGACAGAGCCTTCCTCAAACCTGTAGTGACTGCCACACTTTGCAAGGACACCGTAGAGGGGGCATGTCCGCGCTCCAACTTCC TCCCGACGCAGCCTCTGATTGGCTCCTGGGCTTATAAGAAACGCGTGAATGAGCAGCTGCCGCGGGCAGAAAGTTGCCGGAGGTCTCCGG GTGGTATCGCCCTTTCCTCTTTGCCAGCCCGCTGGCGAGCCGAGCCAGGGCAAGATGAGGTCGTCCTGTGTCCTGCTCACCGCCCTGGTG GCGCTGGCCGCCTATTACGTCTACATCCCGCTGCCTGGCTCCGTGTCCGACCCCTGGAAGCTGATGCTGCTGGACGCCACTTTCCGGGGT GCACAGCAAGTGGATACTTTTGTGGAACTCTATGGGAACAATGCAGCAGCCGAGAGCCGAAAGGGCCAGGAACGCTTCAACCGCTGGTTC CTGACGGGCATGACTGTGGCCGGCGTGGTTCTGCTGGGCTCACTCTTCAGTCGGAAATGACCAGACACTGACCATCCACTCTACCCTCCC ACCCCCTTCTCTGCTCCACCACATCCTCCGTCCAGCCGCCATTGCCACCAGGAGAACCACTACATGCAGCCCATGCCCACCTGCCCATCA CAGGGTTGGGCCCAGATCTGGTCCCTTGCAGCTAGTTTTCTAGAATTTATCACACTTCTGTGAGACCCCCACACCTCAGTTCCCTTGGCC TCAGAATTCACAAAATTTCCACAAAATCTGTCCAAAGGAGGCTGGCAGGTATGGAAGGGTTTGTGGCTGGGGGCAGGAGGGCCCTACCTG ATTGGTGCAACCCTTACCCCTTAGCCTCCCTGAAAATGTTTTTCTGCCAGGGAGCTTGAAAGTTTTCAGAACCTCTTCCCCAGAAAGGAG ACTAGATTGCCTTTGTTTTGATGTTTGTGGCCTCAGAATTGATCATTTTCCCCCCACTCTCCCCACACTAACCTGGGTTCCCTTTCCTTC CATCCCTACCCCCTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATAAAGATGCAAGGACCAGGACTCCCTC CTCACCTCTGGACTGGCTAGAGTCCTCACTCCCAGTCCAAATGTCCTCCAGAAGCCTCTGGCTAGAGGCCAGCCCCACCCAGGAGGGAGG GGGCTATAGCTACAGGAAGCACCCCATGCCAAAGCTAGGGTGGCCCTTGCAGTTCAGCACCACCCTAGTCCCTTCCCCTCCCTGGCTCCC ATGACCATACTGAGGGACCAACTGGGCCCAAGACAGATGCCCCAGAGCTGTTTATGGCCTCAGCTGCCTCACTTCCTACAAGAGCAGCCT GTGGCATCTTTGCCTTGGGCTGCTCCTCATGGTGGGTTCAGGGGACTCAGCCCTGAGGTGAAAGGGAGCTATCAGGAACAGCTATGGGAG CCCCAGGGTCTTCCCTACCTCAGGCAGGAAGGGCAGGAAGGAGAGCCTGCTGCATGGGGTGGGGTAGGGCTGACTAGAAGGGCCAGTCCT GCCTGGCCAGGCAGATCTGTGCCCCATGCCTGTCCAGCCTGGGCAGCCAGGCTGCCAAGGCCAGAGTGGCCTGGCCAGGAGCTCTTCAGG CCTCCCTCTCTCTTCTGCTCCACCCTTGGCCTGTCTCATCCCCAGGGGTCCCAGCCACCCCGGGCTCTCTGCTGTACATATTTGAGACTA GTTTTTATTCCTTGTGAAGATGATATACTATTTTTGTTAAGCGTGTCTGTATTTATGTGTGAGGAGCTGCTGGCTTGCAGTGCGCGTGCA CGTGGAGAGCTGGTGCCCGGAGATTGGACGGCCTGATGCTCCCTCCCCTGCCCTGGTCCAGGGAAGCTGGCCGAGGGTCCTGGCTCCTGA GGGGCATCTGCCCCTCCCCCAACCCCCACCCCACACTTGTTCCAGCTCTTTGAAATAGTCTGTGTGAAGGTGAAAGTGCAGTTCAGTAAT >In-frame_NCEH1_ENST00000538775_chr3_172428637_-_BCL2L1_ENST00000376062_chr20_30253889_-_2007nt AGAGCAGCGACAGAGCCTTCCTCAAACCTGTAGTGACTGCCACACTTTGCAAGGACACCGTAGAGGGGGCATGTCCGCGCTCCAACTTCC TCCCGACGCAGCCTCTGATTGGCTCCTGGGCTTATAAGAAACGCGTGAATGAGCAGCTGCCGCGGGCAGAAAGTTGCCGGAGGTCTCCGG GTGGTATCGCCCTTTCCTCTTTGCCAGCCCGCTGGCGAGCCGAGCCAGGGCAAGATGAGGTCGTCCTGTGTCCTGCTCACCGCCCTGGTG GCGCTGGCCGCCTATTACGTCTACATCCCGCTGCCTGGCTCCGTGTCCGACCCCTGGAAGCTGATGCTGCTGGACGCCACTTTCCGGGGT GCACAGCAAGTGGATACTTTTGTGGAACTCTATGGGAACAATGCAGCAGCCGAGAGCCGAAAGGGCCAGGAACGCTTCAACCGCTGGTTC CTGACGGGCATGACTGTGGCCGGCGTGGTTCTGCTGGGCTCACTCTTCAGTCGGAAATGACCAGACACTGACCATCCACTCTACCCTCCC ACCCCCTTCTCTGCTCCACCACATCCTCCGTCCAGCCGCCATTGCCACCAGGAGAACCACTACATGCAGCCCATGCCCACCTGCCCATCA CAGGGTTGGGCCCAGATCTGGTCCCTTGCAGCTAGTTTTCTAGAATTTATCACACTTCTGTGAGACCCCCACACCTCAGTTCCCTTGGCC TCAGAATTCACAAAATTTCCACAAAATCTGTCCAAAGGAGGCTGGCAGGTATGGAAGGGTTTGTGGCTGGGGGCAGGAGGGCCCTACCTG ATTGGTGCAACCCTTACCCCTTAGCCTCCCTGAAAATGTTTTTCTGCCAGGGAGCTTGAAAGTTTTCAGAACCTCTTCCCCAGAAAGGAG ACTAGATTGCCTTTGTTTTGATGTTTGTGGCCTCAGAATTGATCATTTTCCCCCCACTCTCCCCACACTAACCTGGGTTCCCTTTCCTTC CATCCCTACCCCCTAAGAGCCATTTAGGGGCCACTTTTGACTAGGGATTCAGGCTGCTTGGGATAAAGATGCAAGGACCAGGACTCCCTC CTCACCTCTGGACTGGCTAGAGTCCTCACTCCCAGTCCAAATGTCCTCCAGAAGCCTCTGGCTAGAGGCCAGCCCCACCCAGGAGGGAGG GGGCTATAGCTACAGGAAGCACCCCATGCCAAAGCTAGGGTGGCCCTTGCAGTTCAGCACCACCCTAGTCCCTTCCCCTCCCTGGCTCCC ATGACCATACTGAGGGACCAACTGGGCCCAAGACAGATGCCCCAGAGCTGTTTATGGCCTCAGCTGCCTCACTTCCTACAAGAGCAGCCT GTGGCATCTTTGCCTTGGGCTGCTCCTCATGGTGGGTTCAGGGGACTCAGCCCTGAGGTGAAAGGGAGCTATCAGGAACAGCTATGGGAG CCCCAGGGTCTTCCCTACCTCAGGCAGGAAGGGCAGGAAGGAGAGCCTGCTGCATGGGGTGGGGTAGGGCTGACTAGAAGGGCCAGTCCT GCCTGGCCAGGCAGATCTGTGCCCCATGCCTGTCCAGCCTGGGCAGCCAGGCTGCCAAGGCCAGAGTGGCCTGGCCAGGAGCTCTTCAGG CCTCCCTCTCTCTTCTGCTCCACCCTTGGCCTGTCTCATCCCCAGGGGTCCCAGCCACCCCGGGCTCTCTGCTGTACATATTTGAGACTA GTTTTTATTCCTTGTGAAGATGATATACTATTTTTGTTAAGCGTGTCTGTATTTATGTGTGAGGAGCTGCTGGCTTGCAGTGCGCGTGCA CGTGGAGAGCTGGTGCCCGGAGATTGGACGGCCTGATGCTCCCTCCCCTGCCCTGGTCCAGGGAAGCTGGCCGAGGGTCCTGGCTCCTGA GGGGCATCTGCCCCTCCCCCAACCCCCACCCCACACTTGTTCCAGCTCTTTGAAATAGTCTGTGTGAAGGTGAAAGTGCAGTTCAGTAAT |
Top |
FusionGenePPI for NCEH1_BCL2L1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| NCEH1 | LYPD3, EVI2A, TMEM38A, ZNRF1, SGTB, COQ9, UGT3A2, NRN1, LRRC3, TMEM231, ST3GAL6, CANT1, AMIGO1, ALG9, LMF2, STAM, BTN2A2, GLB1L2, UGT8, POMT1, C1QL1, EIF2AK3, CD1E, ITPRIP, FAM69A, TMTC3, CANX, CD151, GALNT7, CCPG1, ITGA7, FAM177A1, HYAL2, SCARB1, ST6GALNAC3, PGAP1, MTFP1 | BCL2L1 | AVEN, BNIP3, RTN1, RTN4, BIK, BAK1, RAD9A, BID, PMAIP1, BCL2L11, BBC3, BAD, BAX, BCL2, HRK, VDAC1, BNIPL, SPNS1, BCL2L14, PPP1CA, CYCS, RAF1, BECN1, BLK, BCAP31, IRS1, CASP9, APAF1, MOAP1, MCL1, IKZF3, CFLAR, PSEN2, PSEN1, CASP2, CASP8, FKBP8, DYNLL1, BNIP1, PGAM5, BLID, UHRF2, PARK7, ZFYVE1, TP53, METTL23, PPHLN1, ZNF219, EDRF1, PDIA4, GLOD4, RBM5, PLD3, DOCK7, ZHX1, UBR1, FBP1, TLE1, ACTB, TP53BP2, LARP1, PTN, PPP1CC, BFAR, CLU, BMF, CRYAA, CRYAB, ATXN3, AKT1, PARK2, PINK1, TPT1, CDKN2A, CASP1, CASP8AP2, BCL2L1, MTOR, GIMAP5, ABL1, ATG5, PDS5A, HNRNPA1, BNIP3L, CREB3, MAPK8, USP14, MTNR1B, PLK1, MAPK9, GSK3A, GSK3B, MAPKAPK2, MAPK14, CDK1, CHEK1, AURKA, PLK3 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for NCEH1_BCL2L1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for NCEH1_BCL2L1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | BCL2L1 | C2239176 | Liver carcinoma | 2 | CTD_human |
| Tgene | BCL2L1 | C0001430 | Adenoma | 1 | CTD_human |
| Tgene | BCL2L1 | C0010417 | Cryptorchidism | 1 | CTD_human |
| Tgene | BCL2L1 | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| Tgene | BCL2L1 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
| Tgene | BCL2L1 | C0018671 | Head and Neck Neoplasms | 1 | CTD_human |
| Tgene | BCL2L1 | C0023895 | Liver diseases | 1 | CTD_human |
| Tgene | BCL2L1 | C0023904 | Liver Neoplasms, Experimental | 1 | CTD_human |
| Tgene | BCL2L1 | C0024121 | Lung Neoplasms | 1 | CTD_human |
| Tgene | BCL2L1 | C0026764 | Multiple Myeloma | 1 | CTD_human |
| Tgene | BCL2L1 | C0027051 | Myocardial Infarction | 1 | CTD_human |
| Tgene | BCL2L1 | C0030297 | Pancreatic Neoplasm | 1 | CTD_human |
| Tgene | BCL2L1 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| Tgene | BCL2L1 | C0235032 | Neurotoxicity Syndromes | 1 | CTD_human |
| Tgene | BCL2L1 | C0242350 | Erectile dysfunction | 1 | CTD_human |
| Tgene | BCL2L1 | C1384666 | hearing impairment | 1 | CTD_human |
| Tgene | BCL2L1 | C1862939 | AMYOTROPHIC LATERAL SCLEROSIS 1 | 1 | CTD_human |
| Tgene | BCL2L1 | C2937358 | Cerebral Hemorrhage | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|